Heroin Addiction and Vaccine Therapy

Treatment Strategies for Heroin/Opioid Addiction

Introduction

This paper examines research on treatment strategies for heroin/opioid addiction, with a focus on three specific approaches: antagonist therapy, aversive therapy, and anti-drug vaccine research.

Antagonist therapy is a type of treatment for heroin addiction that works by blocking the effects of the drug. It is typically used in conjunction with other forms of treatment, such as counseling and behavioral therapy. There are two main types of antagonists: natural and synthetic. Natural antagonists, such as naltrexone, bind to the same receptors in the brain as heroin, but they do not produce the same effects. Synthetic antagonists, on the other hand, are designed to bind more strongly to the receptors and prevent heroin from binding at all. Both types of antagonists have been shown to be effective in reducing heroin use and preventing relapse. However, they are not without side effects, and they must be used in combination with other treatments to be most effective.

Aversive therapy is a treatment for substance abuse that uses negative reinforcement to discourage drug use. Aversive therapy can take many forms, but all methods share the goal of making drug use unpleasant or uncomfortable in order to decrease the likelihood of relapse. A common form of aversive therapy for heroin/opioid addiction is the administration of naloxone, a medication that blocks the effects of opioids. Naloxone is typically given in combination with a potent opiate such as buprenorphine, and the two drugs are alternated on a daily basis. When used as part of a comprehensive treatment plan, aversive therapy can be an effective tool for helping people overcome addiction.

Though vaccines are most commonly associated with protecting against communicable diseases, there is a growing body of research examining their potential to treat a wide variety of conditions, including addiction. A vaccine against addiction would work by creating antibodies that bind to and neutralize the drug molecules, preventing them from reaching the brain and producing the reinforcing effects that maintain addictive behaviors. Several attempts have been made to develop a vaccine for opioid use disorder, and though none have yet been approved for human use, several show promise. One study found that a vaccine was effective in reducing drug-seeking behavior in rats, and another found that a vaccine was able to block the reinforcing effects of heroin in monkeys. These findings suggest that a vaccine could be an effective treatment for opioid use disorder, though further research is needed to confirm these results.

Summaries

Bell and Strang (2020) summarize relevant literature on drug treatment for opioid addiction. In their review they do not provide systematic analysis but simply cover the general area regarding the field. Their main points are that Opioid Use Disorder (OUD) is a chronic condition and that strong evidence exists indicating that medications like methadone (a full opioid agonist), buprenorphine (a partial agonist) and naltrexone (an opioid antagonist) are effective for treating OUD. In their report, they describe how methadone and buprenorphine work by suppressing opioid withdrawal symptoms, and by attenuating the effects of other opioids. They also discuss how naltrexone inhibits the effects of opioid agonists. One point they emphasize is that the bulk of the evidence, or the most significant evidence shows that oral methadone has the greatest effectiveness. Studies on its use show that longer treatment using oral methadone typically results in the re-establishment of social connections for the addict and other positive outcomes. However, one final point they make is that treatments for OUD are often limited due to inadequate treatment recommendations from health care providers, propensity for relapse and the potentially heightened risk of overdose upon ending treatment.

Bisaga et al. (2018) examined literature from the 1960s onwards to evaluate research on antagonist therapy, particularly focusing on the evolution of treatment strategies for managing opioid withdrawal and the use of naltrexone. They note that new practices involve extended-release naltrexone with agonist tapers and adjuvant medications. However, they also highlight the clinical challenges that remain, such as the need to manage withdrawal and ongoing addiction while the patient receives treatment. They also point out that various clinical factors should be considered when providing treatment for each individual patient, with naltrexone, particularly with the level of opioid abuse and what the patient is comfortable with. Finally, the authors emphasize that most patients do not receive effective treatment for managing relapse.

Murphy (2020) conducted a retrospective analysis of 2018 data obtained through the National Survey on Drug Use and Health and the CDC WONDER Database so as to understand the value of OUD aversion for addicts ages12 through 71, from their own perspective. The findings show that the economic consequences of addiction may be the best form of negative reinforcement therapy and that this should be further explored by researchers in the field. Murphy (2020) relies on economic data from the data sources for analysis and did not obtain any new data for the study.

Pantazis et al. (2021) focus on how pain triggers drive opioid use and they explore sex differences in abusers of opioid. Their main takeaway is that withdrawal symptoms arise when an individual stops taking opioids after extended use and any negative experience (anxiety, etc.) can trigger these withdrawal symptoms. In response, individuals tend to seek out and consume opioids in order to relieve their discomfort and have no aversive therapy in place for countering this reinforcement. Their argument is that withdrawal itself is so aversive that addicts will run back to the drug to avoid this aversion. While it may initially help to temporarily relieve the uncomfortable symptoms of withdrawal, it can ultimately lead to further drug use and addiction. Therefore, the researchers conclude that it is important to be aware of the potential role that environmental stimuli can play in promoting motivated behavior for opioids.

The National Institutes of Health (NIH, 2022) reports on the state of anti-drug vaccines, explaining that the vaccine theoretically produces antibodies that bind to opioids, preventing them from crossing the blood-brain border. The first test is set to use an oxycodone vaccine in a facility with a small test sample of participants. Researchers will be looking to see how long the vaccine is effective and whether it might have any clinical value.

Hwang et al. (2019) explore the most recent results of research on heroine vaccines with a view towards enhancing the vaccine’s effectiveness. They look in particular at the protein Hsp70 and its role as an antigen and as a potential dual carrier-adjuvant. Their research suggests that the protein may serve as an effective mediator in blocking heroin’s psychoactivity, and the research appears to open new avenues for further research on the matter.

Purpose

As Murphy (2020) points out, the topic of treatment strategies is important to study because the costs of not addressing the issue of addiction and relapse are so high. The use of opioids and heroin has become a significant public health issue in recent years. As the NIH (2022) notes, over 2 million Americans suffer from addiction to these substances. While there are many factors that contribute to this problem, one significant factor is the lack of effective treatment options. Currently, the main treatment strategies for opioid/heroin addiction are based on abstinence and harm reduction (Bisaga et al., 2018). However, neither of these approaches has been shown to be effective in the long-term. As a result, there is a need for new treatment strategies that can help to reduce the harmful effects of these substances. The study of treatment strategies for opioid/heroin addiction is important because it can help to identify new approaches that may be more effective in the long-term. It is also important because it can help to improve our understanding of the factors that contribute to addiction. The treatment strategies examined by these researchers focus primarily on antagonist, aversion, and vaccine therapies, each having its own strengths and limitations.

Research Methods

Various treatment strategies for opioid/heroin addiction have been investigated, including antagonist, aversion, and vaccine therapies (Bisaga et al., 2018; Pantazis et al., 2021). Antagonist therapy employs drugs that bind to the same receptors as opioids but do not produce the same psychoactive effects. Aversion therapy uses drugs that cause unpleasant side effects, such as nausea and vomiting, in order to discourage drug use. Vaccine therapy involves creating a vaccine that induces antibodies that bind to opioids, making them unavailable for use by the body. Each of these treatment strategies has been studied in clinical trials in order to determine its efficacy in treating opioid/heroin addiction. In general, trials have found that all three treatment strategies can be effective in reducing drug use and helping individuals to abstain from drug use (Bell & Strang, 2020; Bisaga et al., 2018; Hwang et al., 2019; Pantazis et al., 2021). However, further research is needed to determine the most effective dosage and administration of these therapies.

Some of the studies are purely literature reviews without any experiments. The experimental studies included Hwang et al. (2019) and NIH (2022). The rest were literature reviews, with the exception of Murphy (2020) providing new data analysis if no new data. Obviously the studies do show promise in limited ways. For instance, one promising approach is antagonist therapy, which involves the use of medication to block the receptors in the brain that are targeted by opioids (Bisaga et al., 2018). This can help to reduce cravings and prevent the person from experiencing the pleasurable effects of opioids, making it less likely that they will continue using.

Results

Antagonist therapy relies on the use of naltrexone, which is an opioid receptor antagonist that blocks the effects of opioids. Aversion therapy employs techniques such as electric shocks or nausea-inducing drugs in order to create an unpleasant association with drug use. Vaccine therapy involves the use of a vaccine that produces antibodies that bind to opioids, preventing them from reaching the brain.

According to the research, antagonist therapy is the most effective and proven of the three treatments studied (Bell & Strang, 2020; Bisaga et al., 2018). Naltrexone was shown to be efficacious in a number of different studies, and it was well-tolerated by patients. In contrast, both aversion therapy and vaccine therapy were found to be less effective and more problematic in terms of duration and balancing against environmental factors, respectively (Hwang et al., 2019; Pantazis et al., 2021). Aversion therapy was often considered too intense for patients, and vaccine therapy was found to be less effective than other treatments mainly because not enough research has been done to prove its reliability and efficacy (NIH, 2022). Overall, antagonist therapy should be recommended more frequently by care providers as it is the most effective treatment option currently available.

Discussion

The development of novel treatment strategies for opioid/heroin addiction is a critical research priority. The National Institute on Health is committed to supporting early-stage research with the goal of identifying new therapeutic approaches that can ultimately be translated into clinical practice. With this goal in mind, NIH is funding a variety of clinical studies on three promising treatment approaches: antagonist therapy, aversion therapy, and vaccine therapy.

Antagonist therapy involves the use of medication to block the effects of opioids at their receptor site in the brain and appears to be the most effective treatment when conducted with naltrexone (Bisaga et al., 2018). Aversion therapy uses techniques such as electric shock or nausea-inducing drugs to create an unpleasant association with opioid use, thereby reducing the urge to use; however, the main obstacle with this approach is that it must be able to counter the aversion that patients have to withdrawal symptoms (Pantazis et al., 2021). Vaccine therapy employs a vaccine that binds to opioids in the bloodstream, rendering them unable to reach the brain and produce euphoric effects, and some headway has been made with regard to the role that certain proteins can play in mediating the psychoactivity of heroin (Hwang et al., 2019; NIH, 2022). Each of these approaches has shown promise in animal models, and human clinical trials are currently underway to determine their efficacy in treating opioid/heroin addiction.

The results of future studies will provide critical information on the potential utility of each approach and will guide future directions for research on treatment strategies for this devastating disease. Future research will likely continue to focus on the efficacy of anti-drug vaccines, how long they last, and whether they can effectively block opioids from crossing the blood-brain barrier. More research should also be done on antagonists to see if they can effectively reduce relapse.

Relapse is the biggest obstacle and challenge in treating addiction for opioids and heroin (Bisaga et al., 2018; Pantazis et al., 2021). There needs to be some critical attention given to this issue accordingly. Addicts who have been through withdrawal and detoxification may find that they are still physically dependent on the drugs. This means that even though they may no longer feel the intense cravings and urges that characterized their addiction, they may still experience strong cravings and be at risk for relapse when they encounter triggers associated with drug use. In addition, many addicts find that the first few months or years after quitting are the most difficult, as they adjust to life without drugs and learn new coping skills to deal with stress and other triggers. As a result, relapse prevention is a key component of any treatment plan for addiction to opioids or heroin. The aversion approach to this problem is not sufficient to counter the pain that these individuals seek to escape from (Murphy, 2020; Patanzis et al., 2021). The antagonist therapeutic approach can be helpful but only to a limited degree in controlling for relapse (Bell & Strang, 2020).